Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

NCT00569127 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

427

Enrollment

NIH

Sponsor class

Conditions

Colorectal Neuroendocrine Tumor G1
Gastric Neuroendocrine Tumor G1
Neuroendocrine Neoplasm
Neuroendocrine Tumor
Neuroendocrine Tumor G2

Interventions

BIOLOGICAL: Bevacizumab
OTHER: Laboratory Biomarker Analysis
DRUG: Octreotide Acetate
BIOLOGICAL: Recombinant Interferon Alfa-2b

Sponsor

National Cancer Institute (NCI)